Market Overview

UPDATE: Credit Suisse Downgrades Amgen to Neutral; Upgrade Catalysts Have Passed

Related AMGN
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 For the Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis(
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

Credit Suisse downgraded Amgen (NASDAQ: AMGN) from Outperform to Neutral and lowered the price target to $90.00.

Credit Suisse commented, "The principal reason for our downgrade is that the 3 key elements of our July 2012 report entitled "Upgrading to Outperform = Agency cost + operational gearing + defensive macro call" have been realized, in our veiw [sic] (Please refer to our note,"Upgrading to Outperform = Agency cost + Operational gearing + Defensive macro call", published on July 25). We believe investors are likely looking for fundamental (i.e., pipeline and strategy) improvements/triggers in 2013. We have made no changes to our P&L estimates."

Amgen closed at $82.07 on Friday.

Posted-In: Credit SuisseAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Most Popular

Related Articles (AMGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free